17 November 2022 - Insulin-dependent diabetics say PHARMAC's decision to delay funding a potentially life-saving device appears to be based on flawed assessments.
They claim continuous glucose monitors - which are publicly funded in Australia and Britain - could save the health sector millions of dollars by allowing diabetics to avoid long-term complications, which can be disabling and even deadly.